Atlantic Health System | Oncology Research
Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Currently participating or participated recently in a BeiGene parent study
Intent to continue or start zanubrutinib treatment after any of the following:
Patient who is currently on zanubrutinib treatment:
Does not meet any protocol-specified criteria for zanubrutinib hold or permanent discontinuation, and, in the opinion of the investigator, will continue to benefit from zanubrutinib treatment
Zanubrutinib-naive patient:
Must meet the following criteria ≤ 15 days before first dose of study drug:
Female participants of childbearing potential and nonsterile males must be willing to use a highly effective method of birth control.
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
500 participants in 2 patient groups
Loading...
Central trial contact
BeiGene
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal